Valuation: Fortress Biotech, Inc.

Market Cap	68.37M 61.09M 56.99M 51.77M 97.5M 6.61B 98.23M 685M 268M 3.36B 257M 251M 10.81B	P/E 2026 *	0.8x	P/E 2027 *	-2.05x
Enterprise Value	68.37M 61.09M 56.99M 51.77M 97.5M 6.61B 98.23M 685M 268M 3.36B 257M 251M 10.81B	EV / Sales 2026 *	0.87x	EV / Sales 2027 *	0.6x
Free-Float	77.3%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news: Fortress Biotech, Inc.

Aug. 13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 13	Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026
May. 14	Fortress Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Journey Medical Corporation secures contract with third major GPO for Emrosi	RE
Mar. 31	Fortress Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 30	Fortress Biotech Unit Closes $205 Million PRV Sale	MT
Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE
Jan. 13	Fortress Biotech seen surging after FDA approval
Jan. 13	Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo	CI
Jan. 13	Fortress Biotech, Cyprium Say FDA Approved Zycubo for Pediatric Patients of Menkes Disease; Shares Rise Pre-Bell	MT
Jan. 13	US FDA approves Fortress Bio and Zydus' treatment for a rare pediatric disease	RE
Jan. 13	Fortress Biotech and Cyprium Therapeutics announce U.S. FDA approval of Zycubo® (copper histidinate), the first and only approved treatment for Menkes disease in the United States	RE

More news

Last Transcript: Fortress Biotech, Inc.

Fortress Biotech, Inc., Q2 2026 Earnings Call, Aug 12, 2026

Aug. 13

More transcripts

Analysts' recommendations: Fortress Biotech, Inc.

25-10-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
25-10-01	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
25-10-01	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
24-03-19	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
23-11-29	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT

More recommendations

Press Releases: Fortress Biotech, Inc.

Sep. 08	Journey Medical Corporation to Participate in September 2026 Investor Conferences	AQ
Sep. 08	Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference	AQ
Aug. 13	Fortress Biotech: Q2 Earnings Snapshot	AQ
Aug. 13	Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
Aug. 12	Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights	AQ

More press releases

News in other languages: Fortress Biotech, Inc.

Jan. 13	Fortress Biotech attendu en forte hausse après une approbation de la FDA
21-09-29	MÄRKTE USA/Nur maue Erholung - Belastungsfaktoren bleiben
21-09-29	MÄRKTE USA/Moderate Erholung von Vortagesabsturz
20-09-30	Israël limite les manifestations dans le cadre de mesures sanitaires
20-09-30	France : l'inflation a ralenti à 0,1% sur un an en septembre

More news

Managers and Directors: Fortress Biotech, Inc.

Manager	Title	Age	Since
Lindsay Rosenwald CEO	Chief Executive Officer	71	2013-12-19
Xiao Qin Lu DFI	Director of Finance/CFO	51	2012-02-21
David Jin DFI	Director of Finance/CFO	36	2022-08-15

Director	Title	Age	Since
Jimmie Harvey BRD	Director/Board Member	74	2008-11-30
Lindsay Rosenwald CHM	Chairman	71	2013-12-19
J. Jay Lobell BRD	Director/Board Member	63	2006-05-31

More insiders

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13RÎ±2 CAR T Cell Program for Glioblastoma), and others.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-07	$2.030	-0.98%	68,623
26-10-06	$2.050	-1.91%	223,985
26-10-05	$2.090	+2.96%	553,819
26-10-02	$2.030	-1.93%	327,172
26-10-01	$2.070	-3.27%	286,248

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.050USD

Average target price

5.000USD

Spread / Average Target

+143.90%

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - Fortress Biotech, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Fortress Biotech, Inc.

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Real-time Estimate Cboe BZX 01:00:46 2026-10-07 pm EDT			5-day change	1st Jan Change
2.050 ^USD	0.00%		-5.14%	-44.54%

Markets		Quality
Nasdaq	FBIO	Delayed
CBOE	FBIO	Real-time

1 day	-0.73%
1 week	-5.14%
Current month	-5.14%
1 month	-25.09%
3 months	-32.11%
6 months	-13.62%
Current year	-44.54%

1 week	2	2.17
1 month	2	2.75
Current year	2	4.53
1 year	2	4.53
3 years	1.24	4.95
5 years	1.24	55.35
10 years	1.24	91.5

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/1/26	David Jin	Free	Chief Financial Officer	1,190	0.0036%
4/1/26	David Jin	Free	Chief Financial Officer	2,967	0.0096%
3/18/26	Lindsay Rosenwald	Free	Chief Executive Officer	475,424	1.5318%

Fortress Biotech, Inc. Stock

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Valuation: Fortress Biotech, Inc.

Chart: Fortress Biotech, Inc.

Latest news: Fortress Biotech, Inc.

Last Transcript: Fortress Biotech, Inc.

Analysts' recommendations: Fortress Biotech, Inc.

Press Releases: Fortress Biotech, Inc.

News in other languages: Fortress Biotech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Fortress Biotech, Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FORTRESS BIOTECH, INC.	0.00%	-5.14%	-33.44%	-52.71%	68.37M
ELI LILLY AND COMPANY	+3.36%	+3.26%	+41.62%	+108.96%	1,032B
JOHNSON & JOHNSON	+2.05%	-1.84%	+37.57%	+63.91%	614B
ABBVIE INC.	+2.59%	+4.59%	+17.51%	+83.49%	471B
MERCK & CO., INC.	+1.01%	-1.48%	+63.41%	+37.00%	350B
ROCHE HOLDING AG	+2.92%	+3.12%	+24.78%	+43.51%	337B
NOVARTIS AG	+2.42%	+0.05%	+14.13%	+36.19%	268B
ASTRAZENECA PLC	+1.86%	-0.81%	-4.69%	+12.20%	246B
AMGEN INC.	+2.55%	-2.18%	+39.52%	+51.85%	218B
GILEAD SCIENCES, INC.	+2.33%	-1.04%	+26.31%	+96.51%	179B
Average	+1.83%	-3.73%	+22.67%	+48.09%	371.49B
Weighted average by Cap.	+2.38%	-3.18%	+32.50%	+69.95%

	2026 *	2027 *
Net sales	78.79M 70.4M 65.68M 59.66M 112M 7.62B 113M 789M 308M 3.88B 296M 289M 12.46B	113M 101M 94.41M 85.75M 162M 10.96B 163M 1.13B 443M 5.57B 425M 416M 17.91B
Net income	88.25M 78.85M 73.56M 66.82M 126M 8.54B 127M 884M 345M 4.34B 331M 324M 13.96B	-37.81M -33.79M -31.52M -28.63M -53.92M -3.66B -54.33M -379M -148M -1.86B -142M -139M -5.98B
Net Debt	-	-